Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 ... for the company’s core I&I business and the recent share pullback following emraclidine’s Phase 2 failure in ...

Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...

AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of ...

Like most major biotech players, Abbvie eyed M&A as a major strategy to build out its pipeline and chart a future. And ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...